Deletion of neuronal <i>Idol</i> ameliorates Alzheimer's disease–related pathologies via APOE receptors
Neuronal, but not microglial, Idol deletion reduces amyloid burden and modulates brain APOE and LDLR levels. Deletion of neuronal Idol increases the levels of APOER2 and VLDLR, the Reelin receptors, in the brain. Single-nuclei RNA sequencing highlights the neuronal IDOL's impact on inhibitory neurons and synaptic organization. Targeting neuronal IDOL may provide multiple therapeutic benefits in Alzheimer's disease by modulating APOE receptors.
Authors
- Kelly Hartigan (ORCID: https://orcid.org/0000-0002-2071-0590)
- Byung-Wook Kim (ORCID: https://orcid.org/0000-0001-8390-7713)
- Sutha K. John (ORCID: https://orcid.org/0000-0002-4642-9174)
- Luke C. Dabin (ORCID: https://orcid.org/0000-0001-6365-291X)
- Brianne McCord (ORCID: https://orcid.org/0000-0003-4532-4044)
- Jungsu Kim (ORCID: https://orcid.org/0000-0002-6931-8581)
- Dominic J. Acri (ORCID: https://orcid.org/0000-0003-1942-0892)
- H. R. Sagara Wijeratne (ORCID: https://orcid.org/0000-0002-8209-5626)
- Md. Mamun Al-Amin (ORCID: https://orcid.org/0000-0003-4234-7152)
- Hande Karahan (ORCID: https://orcid.org/0000-0003-3192-7362)
- Do‐Hun Lee (ORCID: https://orcid.org/0000-0001-6840-7841)
- Daniel C. Smith (ORCID: https://orcid.org/0000-0002-2910-6533)
- Hannah M. Rondon Cordero
Institutions
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz.70949
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alzheimer's Association
- Eli Lilly and Company
- Lilly Endowment
- National Institutes of Health
- School of Medicine, Indiana University